PET imaging of occult tumours by temporal integration of tumour-acidosis signals from pH-sensitive 64Cu-labelled polymers

Owing to the diversity of cancer types and the spatiotemporal heterogeneity of tumour signals, high-resolution imaging of occult malignancy is challenging. 18F-fluorodeoxyglucose positron emission tomography allows for near-universal cancer detection, yet in many clinical scenarios it is hampered by false positives. Here, we report a method for the amplification of imaging contrast in tumours via the temporal integration of the imaging signals triggered by tumour acidosis. This method exploits the catastrophic disassembly, at the acidic pH of the tumour milieu, of pH-sensitive positron-emitting neutral copolymer micelles into polycationic polymers, which are then internalized and retained by the cancer cells. Positron emission tomography imaging of the 64Cu-labelled polymers detected small occult tumours (10–20 mm3) in the brain, head, neck and breast of mice at much higher contrast than 18F-fluorodeoxyglucose, 11C-methionine and pH-insensitive 64Cu-labelled nanoparticles. We also show that the pH-sensitive probes reduce false positive detection rates in a mouse model of non-cancerous lipopolysaccharide-induced inflammation. This macromolecular strategy for integrating tumour acidosis should enable improved cancer detection, surveillance and staging.The detection of small tumours with PET is significantly enhanced by temporal integration of the imaging signals, triggered by the acidic milieu of cancers, from pH-sensitive positron-emitting polycationic polymers.

[1]  Jinming Gao,et al.  Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. , 2010, Cancer research.

[2]  J. Wendt,et al.  Atlas of Confounding Factors in Head and Neck PET/CT Imaging , 2011, Clinical nuclear medicine.

[3]  A. Gown,et al.  HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. , 2000, American journal of clinical pathology.

[4]  S. Mittal,et al.  Comparison of Amino Acid Positron Emission Tomographic Radiotracers for Molecular Imaging of Primary and Metastatic Brain Tumors , 2014, Molecular imaging.

[5]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[6]  Yang Li,et al.  Cooperativity Principles in Self-Assembled Nanomedicine. , 2018, Chemical reviews.

[7]  Yana K Reshetnyak,et al.  A novel technology for the imaging of acidic prostate tumors by positron emission tomography. , 2009, Cancer research.

[8]  Osama Mawlawi,et al.  PET/CT in the thorax: pitfalls. , 2014, Radiologic clinics of North America.

[9]  Valerie A Longo,et al.  PET Imaging of Extracellular pH in Tumors with 64Cu- and 18F-Labeled pHLIP Peptides: A Structure–Activity Optimization Study , 2016, Bioconjugate chemistry.

[10]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[11]  Eun Jeong Lee,et al.  Annexin V Imaging Detects Diabetes-Accelerated Apoptosis and Monitors the Efficacy of Benfotiamine Treatment in Ischemic Limbs of Mice , 2014, Molecular imaging.

[12]  J. Daouk,et al.  A practical way to improve contrast-to-noise ratio and quantitation for statistical-based iterative reconstruction in whole-body PET imaging. , 2009, Medical physics.

[13]  S. Mittal,et al.  Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. , 2014, Molecular imaging.

[14]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[15]  G. Cook,et al.  Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.

[16]  O. Ratib,et al.  FDG-PET/CT pitfalls in oncological head and neck imaging , 2014, Insights into Imaging.

[17]  R. Deberardinis,et al.  A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals , 2013 .

[18]  Mark Muzi,et al.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging , 2015, The Journal of Nuclear Medicine.

[19]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[20]  Debiao Li,et al.  pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. , 2015, Neuro-oncology.

[21]  Hyunsuk Shim,et al.  Metabolic positron emission tomography imaging in cancer detection and therapy response. , 2011, Seminars in oncology.

[22]  Tristan Barrett,et al.  Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes , 2009, Nature Medicine.

[23]  Baran D. Sumer,et al.  Ultra-pH-Sensitive Nanoprobe Library with Broad pH Tunability and Fluorescence Emissions , 2014, Journal of the American Chemical Society.

[24]  S. Paik,et al.  HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. , 2000, Journal of the National Cancer Institute.

[25]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[26]  Baran D. Sumer,et al.  A Broad Nanoparticle-Based Strategy for Tumor Imaging by Nonlinear Amplification of Microenvironment Signals , 2013, Nature materials.

[27]  Riemer H. J. A. Slart,et al.  Value of 11C-methionine PET in imaging brain tumours and metastases , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  R. Gillies,et al.  31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. , 1994, The American journal of physiology.

[29]  O. Thews,et al.  Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  E. Jähde,et al.  pH in human tumour xenografts: effect of intravenous administration of glucose. , 1993, British Journal of Cancer.

[31]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[32]  C. Snyderman,et al.  Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[33]  Salvador Tomas,et al.  Multivalence cooperativity leading to “all-or-nothing” assembly: the case of nucleation-growth in supramolecular polymers† †Electronic supplementary information (ESI) available: Experimental methods, including sample preparation for NMR, UV and electron microscopy experiments, the building up of the , 2016, Chemical science.

[34]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[35]  R.J. Gillies,et al.  pH imaging , 2004, IEEE Engineering in Medicine and Biology Magazine.

[36]  Yana K Reshetnyak,et al.  Family of pH (low) insertion peptides for tumor targeting , 2013, Proceedings of the National Academy of Sciences.

[37]  A. Perkins,et al.  Prevalence and pattern of brown adipose tissue distribution of 18F-FDG in patients undergoing PET-CT in a subtropical climatic zone , 2013, Nuclear medicine communications.

[38]  Maurizio Conti,et al.  A method to assess image quality for Low-dose PET: analysis of SNR, CNR, bias and image noise , 2016, Cancer Imaging.

[39]  A. Scarsbrook,et al.  False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. , 2011, Clinical radiology.

[40]  Z. Rumboldt,et al.  PET/CT in the assessment of previously treated skull base malignancies , 2009, Head & neck.

[41]  David W Townsend,et al.  PET/CT artifacts. , 2011, Clinical imaging.

[42]  J. Williamson,et al.  Cooperativity in macromolecular assembly. , 2008, Nature chemical biology.

[43]  Mark Muzi,et al.  Continuing Education: Multi-modality Brain Tumor Imaging – MRI, PET, and PET/MRI , 2015 .

[44]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[45]  I. Schmalfuss Positron Emission Tomography in Head and Neck Cancer , 2020, Medical Radiology.

[46]  Richard L Wahl,et al.  "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  Baran D. Sumer,et al.  A Transistor-like pH Nanoprobe for Tumour Detection and Image-guided Surgery , 2016, Nature Biomedical Engineering.

[48]  J S Fowler,et al.  A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  K. Matyjaszewski,et al.  "Green" atom transfer radical polymerization: from process design to preparation of well-defined environmentally friendly polymeric materials. , 2007, Chemical reviews.

[50]  S. Hess,et al.  FDG-PET/CT in Infectious and Inflammatory Diseases. , 2014, PET clinics.

[51]  G. Gladish,et al.  Integrated Positron Emission Tomography/Computed Tomography in Patients With Non-Small Cell Lung Cancer: Normal Variants and Pitfalls , 2005, Journal of computer assisted tomography.

[52]  Thomas Czech,et al.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.